11 Dec 2009 07:00
Omega Diagnostics plc
("Omega" or the "Company")
Trading Update
The Board indicated in the Company's interim results released on 27th November 2009 that additional growth in Genarrayt sales depended on a resolution to improving the method of manufacturing of these slides. The Board has been continually reviewing the capabilities of the non-contact printing system for manufacturing the Genarrayt slides on a consistent basis. However, following a further technical review of the process today the Board has concluded that until the issues with the manufacturing process are fully resolved the Company will revert solely to the previous manufacturing method. Under the previous manufacturing method the number of slides that can be manufactured is lower than using the non-contact printing system. Consequently, the Board now advises that revenue for the year ended 31 March 2010 is expected to be marginally lower than its previous expectations and that there will be a consequential impact on adjusted profit before tax.
| Omega Diagnostics Group PLC | Walbrook PR Ltd |
| Tel: 01259 763 030 | Paul McManus |
| Andrew Shepherd, Chief Executive | Tel: 020 7933 8787 |
| Kieron Harbinson, Finance Director | Mob: 07980 541 893 |
| www.omegadiagnostics.com | paul.mcmanus@walbrookpr.com Cenkos Securities plc Nomad and Broker Nick Wells/Andy Roberts Tel: 020 7397 8900 |